Home Capital Broker's Calls

A case of no pain no gain for iX Biopharma

Michelle Zhu
Michelle Zhu10/13/2016 01:03 PM GMT+08  • 2 min read
A case of no pain no gain for iX Biopharma
SINGAPORE (Oct 13): DBS Group Research has derived a fair value estimate of 43 cents for iX Biopharma in its preliminary assessment of what it deems a high-risk stock, with a view that investors should expect 0-20% potential returns from the stock over th
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

SINGAPORE (Oct 13): DBS Group Research has derived a fair value estimate of 43 cents for iX Biopharma in its preliminary assessment of what it deems a high-risk stock, with a view that investors should expect 0-20% potential returns from the stock over the next 12 months.

The specialty pharmaceutical company currently has five drugs under development: WafeRest for jetlag and improved sleep quality; PheoniX for the treatment of male erectile dysfunction; as well as Wafermine, BnoX and Wafernyl for pain management.

All five drugs leverage on an under-the-tongue delivery technology, WaferiX, which enables quicker absorption and increases the bioavailability of the drugs such that a lower dosage is required.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.
Unlock unlimited access to premium articles with less than $9 per month. Subscribe Now